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OBJECTIVES The study evaluated the effects of metoprolol, a pure beta-blocker, and d,l-sotalol, a
beta-blocker with additional class III antiarrhythmic effects, on microvolt-level T-wave
alternans (TWA).
BACKGROUND Assessment of TWA is increasingly used for purposes of risk stratification in patients prone
to sudden death. There are only sparse data regarding the effects of beta-blockers and
antiarrhythmic drugs on TWA.
METHODS Patients with a history of documented or suspected malignant ventricular tachyarrhythmias were
eligible. All patients underwent invasive electrophysiologic (EP) testing including programmed
ventricular stimulation and determination of TWA at increasing heart rates using atrial pacing.
Reproducibility of TWA at two consecutive drug-free baseline measurements was tested in a
random patient subset. Following baseline measurements, all patients were randomized either to
double-blind intravenous infusion of sotalol (1.0 mg/kg) or metoprolol (0.1 mg/kg). Results of
TWA assessment at baseline and after drug exposure were compared.
RESULTS Fifty-four consecutive patients were studied. In 12 patients, repetitive baseline measurement
of TWA revealed stable alternans voltage (Valt) values (9.1  5.8 V vs. 8.5  5.7 V, p 
NS). After drug administration, Valt decreased by 35% with metoprolol (7.9  6.0 V to
4.9  4.2 V; p  0.001) and by 38% with sotalol (8.6  6.8 V to 4.4  2.3 V; p 
0.001). In eight patients with positive TWA at baseline, repeated measurement revealed
negative test results.
CONCLUSIONS In patients prone to sudden cardiac death, there is a reduction in TWA amplitude following
the administration of antiadrenergic drugs. This result indicates that TWA is responsive to
the pharmacologic milieu and suggests that, to assess a patient’s risk of spontaneous
ventricular arrhythmia, the patient should be tested while maintaining the pharmacologic
regimen under which the risk of arrhythmia is being assessed. This applies particularly for
beta-blocker therapy. (J Am Coll Cardiol 2001;38:2013–9) © 2001 by the American College
of Cardiology
Microvolt-level T-wave alternans (TWA) that is not visibly
apparent on the electrocardiogram (ECG) can be detected
during atrial pacing or during submaximal exercise, resulting
in modest heart rate increases in patients with ventricular
arrhythmias but not in control subjects (1). Assessment of
TWA is increasingly used to stratify patients with heart
disease for their risk of sudden arrhythmogenic death (2–5).
Pastore and associates (6) recently demonstrated in a series
of elegant experiments using high-density optical mapping
techniques that there is a close link between TWA and the
underlying mechanism of reentry. According to this mech-
anism, above a critical threshold heart rate, action potentials
from neighboring cells alternate with opposite phase that
greatly amplifies spatial dispersions of repolarization, which,
in turn, form the substrate for unidirectional block and
re-entry.
The influence of the autonomic nervous system on TWA
is incompletely understood. Whereas previous investiga-
tions provided evidence for a role of the sympathetic limb in
eliciting TWA (7), recent observations by Kaufman et al.
(8) suggest that sympathetic activation is not mandatory for
the occurrence of arrhythmogenic TWA. Similarly, only
sparse data exist on the modulating effects of antiarrhythmic
drugs on TWA (9,10). From a clinical perspective, however,
these issues are of particular importance because most
patients at risk for serious ventricular arrhythmias are
treated with antiadrenergic drugs and many are receiving
antiarrhythmic drugs, which prolong ventricular repolariza-
tion. Accordingly, the present prospective study was de-
signed to evaluate specifically the effects of metoprolol, a
pure beta-blocker, and sotalol, a beta-blocker with addi-
tional class III antiarrhythmic effects (11), on microvolt-
level TWA in patients prone to sudden cardiac death.
METHODS
Patient population. Consecutive patients who were re-
ferred to the arrhythmia service of the J.W. Goethe Uni-
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versity, Frankfurt, Germany, for evaluation of ventricular
tachyarrhythmias were eligible for participation if they had
one of the following: an episode of survived out-of-hospital
cardiac arrest; documented sustained monomorphic ventric-
ular tachycardia (VT); syncope in the presence of significant
organic heart disease; or of nonsustained VT and reduced
left ventricular function in the setting of chronic coronary
artery disease (CAD). All patients had undergone extensive
noninvasive and invasive diagnostic evaluation to establish
the underlying heart disease. Patients were excluded if they
had evidence of active ischemia, were in atrial fibrillation, or
if a permanent pacemaker had previously been implanted.
Patients receiving chronic amiodarone treatment were also
excluded. All patients gave informed consent prior to
enrollment in the study.
Study protocol. ELECTROPHYSIOLOGIC STUDY. Previously
administered antiarrhythmic drugs and beta-blockers were
withheld for at least 5 half-lives prior to electrophysiologic
(EP) study. Three multipolar electrode catheters were po-
sitioned via the right or left femoral vein in the high right
atrium, the right ventricular apex and the His bundle region.
Programmed ventricular stimulation was performed accord-
ing to a standardized protocol at two different sites (right
ventricular [RV] apex; RV outflow tract) at basic cycle
lengths of 600, 500 and 430 ms using one to three
extrastimuli. The results of the EP study were defined as
positive if sustained monomorphic VT or ventricular fibril-
lation (VF) was repeatedly induced. According to these
results, patients were assigned to two different randomiza-
tion strata (Fig. 1).
Assessment of TWA. For assessment of microvolt TWA,
the spectral method described by Smith et al. (12) was
applied using the system CH2000 (Cambridge Heart,
Bedford, Massachusetts). This measurement has been de-
scribed in detail elsewhere (13,14). Because of the low-
amplitude nature of TWA, particular attention was paid to
ensure adequate signal quality during TWA recording.
Standard ECG leads along with the Frank orthogonal
(XYZ) configuration were utilized. Multicontact silver–
silver chloride electrodes specifically designed for noise
reduction (HiRes, Cambridge Heart) were used. The TWA
was measured using atrial stimulation at increasing heart
rates of from 90 to 130 beats/min. Each pacing cycle length
was maintained for at least 3 min. The TWA was defined as
positive if the TWA voltage (Valt) was 1.9 V (at rest
1.0 V) with the alternans ratio K—a measure of TWA
significance—being 3.
Measurement of TWA voltage. The TWA recordings
were interpreted by one of the investigators (T. K.) who was
unaware of the patient’s history, the drug administered,
inducibility, or the sequence of TWA recordings. The
magnitude of TWA voltage (Valt) in individual patients was
measured as follows: TWA spectra were printed (Fig. 2)
and the two recordings of each patient compared as to the
quality of the recordings at different corresponding heart
rates. The Valt was measured at the highest common heart
rate by picking the highest amplitude from the TWA trend
summary of baseline and on-drug recordings. Because
TWA amplitude is usually most pronounced in the precor-
dial leads V2 through V4, these leads were selected for Valt
determination.
Assessment of TWA reproducibility. Intraindividual re-
producibility of TWA measurements during baseline was
assessed in 12 randomly selected patients. These patients
underwent two repetitive baseline TWA assessments
30 min apart from each other prior to randomization to
drug treatment.
Abbreviations and Acronyms
CAD  coronary artery disease
ECG  electrocardiogram/electrogardiographic
EP  electrophysiologic
ERP  effective refractory period
ICD  implantable cardioverter-defibrillator
LVEF  left ventricular ejection fraction
RV  right ventricular
TWA  T-wave alternans
Valt  alternans voltage
VF  ventricular fibrillation
VT  ventricular tachycardia
Figure 1. Study protocol. EP  electrophysiologic; TWA  T-wave alternans; VF  ventricular fibrillation; VT  ventricular tachycardia.
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Randomized intervention. After completion of baseline
measurements, patients were randomized in a double-blind
fashion to either metoprolol or d,l-sotalol treatment. Ran-
domization was performed in two separate strata according
to inducibility at EP testing (Fig. 1). Study drug was
administered intravenously over 5 min at a dose of 1 mg/kg
sotalol or a dose of 0.1 mg/kg metoprolol. On-drug TWA
measurement was started 10 min after the end of drug
infusion. Resting heart rate and ventricular effective refrac-
tory period (ERP) were also determined for comparison
with baseline values.
Statistical analysis. Differences within and between (inter-
action) the two treatment groups with regard to the changes
in heart rate, ERP, and TWA amplitude were performed
using the two-way repeated measures analysis of variance
(Statistical Package for Social Sciences [SPSS], version 7.0).
Mean values and standard deviations are given. A p value
0.05 was defined as statistically significant.
RESULTS
Baseline characteristics. A total of 65 patients (mean age
61  10 years; left ventricular ejection fraction [LVEF]
37  13%) were included in the study. Of these, 11 had to
be excluded from the final data analysis for the following
reasons: high incidence of spontaneous ventricular extrasys-
toles during atrial stimulation preventing accurate TWA
determination in seven patients; increase in Wenckebach
point after drug administration excluding comparison of
TWA at corresponding heart rates in two patients; and
Figure 2. Reproducibility of T-wave alternans (TWA) analysis. (A) TWA amplitudes (alternan voltage [Valt]) at two repetitive drug-free baseline
measurements in 12 patients. (B) Representative TWA recordings in a patient with stable TWA amplitutes (Valt) at repetitive drug-free measurements
(NS  not significant). BPM  beats per minute; HR  heart rate.
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occurrence of sustained VT during baseline TWA testing in
two patients. Accordingly, this report is based on analysis of
the data obtained in 54 patients. Of these, 38 patients (70%)
had CAD, whereas 16 (30%) had nonischemic cardiomy-
opathy (Table 1).
Results of EP testing and baseline TWA assessment.
Sustained VT or VF was induced in 29 of 54 patients (54%),
specifically in 25 of 38 patients (66%) with CAD and in 4
of 16 patients (25%) with nonischemic cardiomyopathy
(p  0.01). Overall, TWA was positive in 48 patients
(89%). The incidence of a positive TWA was not signifi-
cantly different in patients with documented VT/VF (32/34
patients; 94%) compared to those with a history of nonsus-
tained VT or syncope (16/20 patients; 80%; p  0.11).
Except for one inducible patient, all patients (97%) were
TWA positive. In noninducible patients, the prevalence of
a positive TWA was lower, with 20 of 25 patients (80%;
p  0.06, compared to inducible patients). Baseline Valt
(8.7 7.1 V vs. 7.7 5.4 V; p 0.56) and TWA onset
heart rate (96  10 beats/min vs. 100  11 beats/min; p 
0.63) were similar in both inducible and noninducible
patients. Repeated baseline TWA testing was performed in
12 randomly selected patients whose demographic charac-
teristics were comparable to those of the entire study cohort.
The TWA amplitude was comparable between both tests
(mean Valt 9.1  5.8 V vs. 8.5  5.7 V; p  0.2; Fig. 2).
A representative example of repetitive drug-free TWA
measurements is shown in Figure 2.
Effects of metoprolol and d,l-sotalol on TWA. Of the 54
patients, 25 received metoprolol and 29 d,l-sotalol. Both
drugs resulted in a comparable decrease in resting heart rate
(metoprolol: 79  12 beats/min to 67  10 beats/min;
sotalol: 75  12 beats/min to 60  9 beats/min; p  0.01
for both comparisons). Ventricular ERP increased signifi-
cantly from 244  26 ms to 276  36 ms (p  0.001) in
patients treated with sotalol and from 237  25 ms to
257  31 ms (p  0.002) in patients receiving metoprolol.
These changes in heart rate and ERP were comparable
within the two treatment groups (p  0.67 and p  0.31,
respectively).
In 8 of 48 patients with positive baseline TWA, the
TWA turned negative after drug administration; five pa-
tients had received metoprolol, and three had received
sotalol. Baseline Valt was lower in these eight patients as
compared to those who remained TWA positive after
beta-blockers (4.1  1.4 V vs. 9.2  6.7 V; p  0.026).
Administration of beta-blockers in these patients reduced
Valt below 2 V. Four of these patients (50%) had inducible
VT/VF compared to 23 of 40 (56%) patients in whom
TWA remained positive after drug administration (p 
0.71). All six patients with a negative TWA at baseline
remained negative after drug administration.
A significant decrease in Valt occurred after drug admin-
istration in the entire patient population (8.4  6.4 V to
4.7  3.3 V; p  0.001) as well as in the subgroup of
patients with CAD (8.2  6.8 V to 4.5  3.5 V; p 
0.001). The decrease in Valt was comparable in patients
receiving metoprolol (7.9  6.0 V vs. 4.9  4.2 V; p 
0.001) and in those treated with sotalol (8.6  6.8 V vs.
4.4  2.3 V; p  0.001). A representative example of
drug-induced reduction in Valt is shown in Figure 3. The
h e a r t r a t e a t w h i c h T W A b e c a m e d e t e c t -
able was similar at baseline and on-drug assessment in both
study groups (metoprolol 94  8 beats/min vs. 95 
7 beats/min; p  0.86; sotalol: 99  10 beats/min vs. 98 
12 beats/min; p  0.83). The observed changes in Valt and
onset heart rate were comparable within the two treatment
groups (p  0.905 and p  0.602, respectively).
DISCUSSION
The major finding of this prospectively designed study is
that the cardioselective beta-blockers metoprolol and so-
talol, which additionally prolongs ventricular repolarization,
exert comparable effects on TWA. Both substances reduce
overall TWA amplitude when measurements are compared
to drug-free baseline assessment. However, TWA ampli-
tude remained well above the conventionally defined level of
significance (1–5). Importantly, only few patients become
TWA-negative after short-term drug administration. An-
other finding worth emphasizing is that repeated measure-
ments of microvolt TWA yielded comparable results. These
findings have implications both with respect to the under-
lying EP mechanism of TWA and for the clinical usefulness
of TWA determination to stratify patients for their risk of
ventricular tachyarrhythmias and sudden cardiac death.
Sympathetic nervous system and TWA. There are con-
flicting reports in the literature on the role of the sympa-
thetic nervous system in triggering TWA. One of the first
observations related to this issue was reported in 1975 by
Schwartz and Malliani (7), who described the case of a
nine-year-old girl with the idiopathic long QT syndrome
who repeatedly showed macroscopic TWA during episodes
of sympathetic excitation. In the same report, experimental
findings in vagotomized cats were described. In these
animals, TWA could be elicited during stimulation of the
left stellate ganglion. Subsequently, several similar observa-
Table 1. Patients’ Demographic Data
N (%)
Age (yrs) 61  10
Male gender 47 (87%)
LVEF (%) 37  13
CAD 38 (70%)
Indication for EP study
Ventricular fibrillation 17 (30%)
Sustained VT 16 (30%)
Nonsustained VT 11 (20%)
Syncope 10 (19%)
EP inducible (%) 29 (54%)
TWA positive (%) 48 (89%)
CAD  coronary artery disease; EP  electrophysiologic; LVEF  left ventricular
ejection fraction; TWA  T-wave alternans; VT  ventricular tachycardia.
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tions in patients afflicted with the long QT syndrome were
reported (15). These experimental findings along with the
clinical observations led to the hypothesis that increases in
sympathetic activity may play a critical role in triggering
TWA as a precursor of malignant ventricular tachyarrhyth-
mias.
In a recent and careful study in patients referred for EP
testing, Kaufman et al. (8) measured TWA at identical
pacing cycle lengths with and without isoproterenol in 14
patients. Five patients with a history of sudden cardiac death
were noninducible at EP testing; in two of these, TWA
increased significantly during adrenergic stimulation. In
another two patients, beta-adrenergic stimulation induced
TWA that was not already present at baseline (8). The
investigators concluded from their observations that there is
only a modest contribution of adrenergic tone to the
occurrence of microvolt TWA in most patients.
In contrast to the report of Kaufman et al. (8), all patients
enrolled in the present study had a history of documented or
suspected malignant ventricular arrhythmia. Administration
of antiadrenergic drugs resulted in a significant decrease in
TWA amplitude in all patients. Of note, however, only a
few patients became TWA-negative after infusion of beta-
blockers. From these observations, therefore, it appears
tempting to speculate that, at least in some patients prone to
sudden cardiac death, sympathetic activation plays a role in
triggering the occurrence of discordant alternans in diseased
regions of the myocardium. This hypothesis accords with
findings demonstrating regional differences in sympathetic
activation in patients after myocardial infarction (16,17).
The findings of the present prospective randomized study
are further supported by preliminary observations reported
on modulation of TWA by autonomic influences (18). The
effects of selective sympathetic (esmolol, n  17) or para-
sympathetic (atropine, n  17) blockade on TWA were
examined in 34 patients with inducible sustained VT. The
Valt decreased with both sympathetic and parasympathetic
blockade, but this decrease was more impressive with
beta-blockade. Specifically, Valt, measured in the vector
magnitude lead, decreased from 2.2  1.9 V to 1.3 
1.9 V (p  0.05) with esmolol, resulting in a decrease of
TWA sensitivity for prediction of EP results, from 71% to
Figure 3. (A) Changes in heart rate following drug administration. (B) Changes in ventricular effective refractory periods following drug administration.
(C) Changes in T-wave alternans (TWA) amplitude following drug administration (Valt) in patients with d,l-sotalol (dark bars) and metoprolol (gray bars).
(D) Representative example of a patient with a significant decrease in Valt in nearly all electrocardiographic leads following administration of d,l-sotalol (left:
before drug administration; right: after drug administration). BPM  beats per minute; HR  heart rate.
2017JACC Vol. 38, No. 7, 2001 Klingenheben et al.
December 2001:2013–9 Effects of Antiarrhythmic Drugs on TWA
35% (p  0.08) (18). In contrast to our study, however, the
baseline Valt was 2.2 V, which is just above the predefined
positivity level of 1.9 V. In the present study, baseline Valt,
measured in the precordial leads, which tends to have a
greater magnitude, averaged 8.4 V, and TWA sensitivity
decreased only from 88% to 72% (p  0.06) with beta-
blockers.
Finally, the well-appreciated benefits of beta-blocker
therapy in preventing sudden arrhythmogenic death support
the notion of a modulating effect of antiadrenergic therapy
on triggers for ventricular tachyarrhythmias such as TWA
(19).
Prolongation of ventricular repolarization by antiar-
rhythmic drugs and TWA. Despite the fact that assess-
ment of microvolt-level TWA is increasingly used for risk
stratification (2–5,20), to the best of our knowledge only
one prospective study deals with the effects of antiarrhyth-
mic drugs on TWA in patients with structural heart disease
(10). Kavesh et al. (10) evaluated the effects of procainamide
on TWA in 24 patients with inducible sustained VT at
baseline and after acute drug loading. The magnitude
of TWA amplitude decreased from 0.6  0.8 V to
0.3  0.4 V during sinus rhythm, from 2.0  1.6 V to
0.7  0.7 V during pacing at 100 beats/min, and
from 3.0  2.0 V to 1.7  1.8 V during pacing at
120 beats/min (p  0.001). This resulted in a decrease in
the sensitivity of TWA for induction of sustained VT from
87% to 60% at a heart rate of 120 beats/min (10). It is again
important to note that the mean TWA amplitude reported
in that trial was markedly lower than that measured in the
present study.
The only study dealing with the effects of class III
antiarrhythmic drugs on TWA is a retrospective analysis
evaluating the prevalence of TWA in relationship to ami-
odarone usage in patients with implantable cardioverter-
defibrillators (ICDs) (9). In that study, Groh et al. (9)
reported that a positive TWA was found only in 1 of 9 ICD
patients (11%) treated with amiodarone as compared with
14 of 22 (64%) patients without antiarrhythmic drug ther-
apy. During follow-up, the presence of TWA predicted
future appropriate ICD therapy for ventricular tachyar-
rhythmias (9).
In our study, the decrease in TWA amplitude observed
after sotalol administration was comparable to that follow-
ing metoprolol infusion. This suggests that the effect of
sotalol on ventricular repolarization is less important in
terms of modulating TWA, at least during short-term
administration.
Clinical implications. The observations from this pros-
pective study have a number of important implications for
the clinical use of TWA determination for risk stratification
in patients with structural heart disease. First, there is a
good intraindividual reproducibility of TWA assessment
in the absence of beta-blockers or antiarrhythmic drugs.
Second, in agreement with previous studies (2–5,13), there
is a patient-specific heart rate threshold at which micro-
volt TWA becomes detectable. In patients with significant
organic heart disease, this threshold is about 90 to
110 beats/min. Third, in patients at high risk for ventricular
tachyarrhythmias, such as the ones enrolled in our study,
TWA is usually measurable even in the presence of antiad-
renergic medication. This prospective study, in conjunction
with the earlier studies cited above (8–10), indicates that
TWA is responsive to the pharmacologic milieu. In partic-
ular, we find here that beta-blockers tend to reduce TWA;
beta-blockers are also known to reduce risk of spontaneous
ventricular arrhythmia. Because cardioactive drugs may alter
TWA and may also modulate susceptibility to spontaneous
ventricular arrhythmias, it would seem to make most sense
to perform TWA testing for purposes of risk stratification
while maintaining the ongoing pharmacologic milieu of the
patient. When the pharmacologic milieu of the patient is
altered, TWA testing should be repeated to determine
whether TWA status is altered.
A specific issue arises in this regard with respect to
beta-blockers. T-wave alternans testing is most commonly
performed noninvasively during stress testing. One effect of
beta-blocker therapy is to limit the peak heart rate that may
be achieved by a patient during exercise stress. Initially, a
stress TWA test was interpreted to be negative if the criteria
for positivity were not met and significant TWA was
documented not to be present for at least 1 min at a heart
rate of at least 105 beats/min (e.g., see Gold et al. [3]).
Patients on beta-blockers frequently cannot attain a heart
rate of 105 beats/min for this period of time and, thus, if not
meeting the criteria for positivity, would be classified as
indeterminate. For this reason, beta-blockers would be
withheld for 24 h prior to TWA testing (3). The present
study demonstrates that testing patients on beta-blockers is
feasible, with only a few patients turning TWA-negative
after the drug.
In a recent study of heart-failure patients without prior
history of ventricular arrhythmias (5) we prospectively
determined not to withhold beta-blockers; accordingly, we
prospectively modified the criteria for negativity to also
include patients who did not meet the criteria for positivity,
who had a maximal stress test achieving a maximum heart
rate of at least 80 beats/min, and who had no significant
alternans for at least 1 min at a heart rate within 5 beats/min
of their maximum rate. None of the patients classified as
negative by this criterion subsequently sustained a ventric-
ular tachyarrhythmic event. These results also suggest that
beta-blockers may reduce arrhythmic risk both via a direct
myocardial effect and also by blocking an arrhythmogenic
increase in heart rate.
Study limitations. The present study must be interpreted
in the face of certain limitations. Because of obvious logistic
reasons, we used only acute drug administration to assess
changes in TWA. This, of course, does not necessarily
imply that the same or similar changes can be observed
during prolonged administration of beta-blockers or sotalol.
A second potential limitation is the fact that we did not
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examine the effects of class I antiarrhythmic drugs. How-
ever, the use of this class of substances in patients with
structural heart disease and serious ventricular arrhythmias
has markedly decreased as the result of numerous prospec-
tive studies, including the Cardiac Arrhythmia Suppression
Trial (21–23).
Conclusions. In patients with a history of documented or
suspected ventricular tachyarrhythmias, there is a reduction
in TWA amplitude following the administration of antiad-
renergic drugs such as metoprolol and d,l-sotalol. This
indicates that TWA is modulated—at least in some pa-
tients—by sympathetic activity. The fact that TWA is
responsive to the pharmacologic milieu—as is the risk of
spontaneous ventricular arrhythmias—suggests that for pur-
poses of risk stratification TWA ought to be determined
without alteration of the patient’s ongoing pharmacologic
regimen.
Reprint requests and correspondence: Dr. Stefan H. Hohn-
loser, Department of Medicine, Division of Cardiology, J. W.
Goethe University, Theodor-Stern-Kai 7, D-60590 Frankfurt,
Germany. E-mail: Hohnloser@em.uni-frankfurt.de.
REFERENCES
1. Costantini O, Drabek C, Rosenbaum DS. Can sudden cardiac death
be predicted from the T wave of the ECG? A critical examination of
T-wave alternans and QT interval dispersion. Pacing Clin Electro-
physiol 2000;23:1407–16.
2. Estes NAM, Michaud G, Zipes DP, et al. Electrical alternans during
rest and exercise as predictors of vulnerability to ventricular arrhyth-
mias. Am J Cardiol 1997;80:1314–8.
3. Gold MR, Bloomfield DM, Anderson KP, et al. A comparison of
T-wave alternans, signal-averaged electrocardiography and pro-
grammed ventricular stimulation for arrhythmia risk stratification.
J Am Coll Cardiol 2000;36:2247–53.
4. Hohnloser SH, Klingenheben T, Li YG, Zabel M, Petermans J,
Cohen RJ. T-wave alternans as a predictor of recurrent ventricular
tachyarrhythmias in ICD recipients: prospective comparison with
conventional risk markers. J Cardiovasc Electrophysiol 1998;12:1258–
68.
5. Klingenheben T, Zabel M, D’Agostino RB, Cohen RJ, Hohnloser
SH. Predictive value of T-wave alternans for arrhythmic events in
patients with congestive heart failure. Lancet 2000;356:651–2.
6. Pastore JM, Girouard SD, Laurita KR, Akar FG, Rosenbaum DS.
Mechanism linking T-wave alternans to the genesis of cardiac fibril-
lation. Circulation 1999;99:1385–94.
7. Schwartz PJ, Malliani A. Electrical alternation of the T wave: clinical
and experimental evidence of its relationship with the sympathetic
nervous system and with the long QT syndrome. Am Heart J
1975;89:45–50.
8. Kaufman ES, Mackall JA, Julka B, Drabek C, Rosenbaum DS.
Influence of heart rate and sympathetic stimulation on arrhythmic
T-wave alternans. Am J Physiol 2000;279:H1248–55.
9. Groh WJ, Shinn TS, Engelstein EE, Zipes DP. Amiodarone reduces
the prevalence of T-wave alternans in a population with ventricular
tachyarrhythmias. J Cardiovasc Electrophysiol 1999;10:1335–9.
10. Kavesh NG, Shorofsky SR, Sarang SE, Gold MR. The effect of
procainamide on T wave alternans. J Cardiovasc Electrophysiol 1999;
10:649–54.
11. Hohnloser SH, Woosley RD. Sotalol. N Engl J Med 1994;331:31–8.
12. Smith JM, Clancy EA, Valeri CR, Ruskin JN, Cohen RJ. Electrical
alternans and cardiac electrical instability. Circulation 1988;77:110–
21.
13. Hohnloser SH, Klingenheben T, Zabel M, Li YG, Albrecht P, Cohen
RJ. T-wave alternans during exercise and atrial pacing in humans.
J Cardiovasc Electrophysiol 1997;8:987–93.
14. Rosenbaum DS, Albrecht P, Cohen RJ. Predicting sudden cardiac
death from T wave alternans of the surface electrocardiogram: promise
and pitfalls. J Cardiovasc Electrophysiol 1996;7:1095–111.
15. Goldman DS, Zareba W, Moss AJ. Malignant T-wave alternans.
Circulation 2000;102:e46–7.
16. Barber MJ, Mueller TM, Henry DP, Felten SY, Zipes DP. Trans-
mural myocardial infarction in the dog produces sympathectomy in
noninfarcted myocardium. Circulation 1983;67:787–96.
17. Zipes DP, Wellens HJJ. Sudden cardiac death. Circulation 1998;98:
2334–51.
18. MacMurdy KS, Kirk MM, Cooklin M, Shorofsky SR, Gold MR. The
effect of selective autonomic blockade on T wave alternans (abstr).
Circulation 1999;100 Suppl:2683.
19. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during
and after myocardial infarction: an overview of the randomized trials.
Prog Cardiovasc Dis 1985;5:335–71.
20. Rosenbaum DS, Jackson LE, Smith JM, Garan H, Ruskin JN, Cohen
RJ. Electrical alternans and vulnerability to ventricular arrhythmias.
N Engl J Med 1994;330:235–41.
21. Echt DS, Liebson PR, Mitchell B, et al. Mortality and morbidity in
patients receiving encainide, flecainide or placebo. The Cardiac Ar-
rhythmia Suppression Trial. N Engl J Med 1991;324:781–8.
22. The Cardiac Arrhythmia Suppression Trial II investigators. Effect of
the antiarrhythmic agent moricizine in survival after myocardial
infarction. N Engl J Med 1992;327:227–33.
23. Mason JW for the Electrophysiologic Study versus Electrocardio-
graphic Monitoring investigators. A comparison of seven antiarrhyth-
mic drugs in patients with ventricular tachyarrhythmias. N Engl J Med
1993;329:452–8.
2019JACC Vol. 38, No. 7, 2001 Klingenheben et al.
December 2001:2013–9 Effects of Antiarrhythmic Drugs on TWA
